Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-02-21

FDA Approved: BUPRENORPHINE AND NALOXONE — Supplemental Application (PAI Holdings, LLC dba Pharmaceutical Associates, Inc. and dba PAI Pharma)

View source ↗

Summary

FDA approved a supplemental application for a generic buprenorphine and naloxone product intended for the treatment of opioid dependence, submitted by PAI Holdi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Buprenorphine and naloxone (BUPRENORPHINE AND NALOXONE)

Snippet

SUPPL AP for BUPRENORPHINE AND NALOXONE (BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE)